Time to bring personalised cell therapies in care of chronic wounds
Our Services
​Therapy for Chronic Wounds
Healiva® is a patient-centric Swiss Biotech company, delivering personalised therapy to improve patient’s quality of life. We use a multi-pronged approach to address patient needs by combining cell therapies, enzyme technology and medical devices to deliver tailored solutions for chronic wounds. We are the first Biotech to offer multiple end-to-end, intuitive wound care products that can be personalised whilst remaining affordable.
Mission
Our mission is to commercialize a portfolio of innovative, personalised and affordable therapies for chronic and acute wounds and targeting key pain points in the patient care pathway. There remains a major gap in the current treatment paradigm. No permanent therapy for non-healing wounds currently exists.
Wounds: A sizeable problem
156M
Chronic wound patients worldwide
​
2-3% of the elderly have painful Venous/Arterial Leg Ulcers
25% of diabetics have disabling diabetic foot ulcers
9.7M
Venous leg ulcers and
10M
Diabetic Foot ulcers patients
€21.7B
in 2022 according to PitchBook Data
8%
CAGR by 2026
Pipeline Products
Healiva Technological Breakthroughs
Healiva products
Indication
Pre-clinical discovery
Pre-clinical development
Ph I/IIa
Ph IIb
Ph III
Market phase
AQUAtryp
Acute & chronic wounds
Healiva 004
VLUs & DFUs / chronic wounds
Healiva 002
VLUs & DFUs / chronic wounds
Epidex
Severe VLUs / chronic wounds
